Gossamer Bio, Inc. (GOSS)
10.11
-0.67
(-6.22%)
USD |
NASDAQ |
Oct 07, 16:00
10.30
+0.19
(+1.88%)
After-Hours: 20:00
Gossamer Bio Net Income (Quarterly) : 16.90M for June 30, 2026
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 16.90M |
| March 31, 2026 | -46.66M |
| December 31, 2025 | -47.24M |
| September 30, 2025 | -48.22M |
| June 30, 2025 | -38.27M |
| March 31, 2025 | -36.64M |
| December 31, 2024 | -33.03M |
| September 30, 2024 | -30.80M |
| June 30, 2024 | 49.23M |
| March 31, 2024 | -41.93M |
| December 31, 2023 | -48.15M |
| September 30, 2023 | -40.01M |
| June 30, 2023 | -42.50M |
| March 31, 2023 | -49.16M |
| December 31, 2022 | -55.76M |
| September 30, 2022 | -59.36M |
| June 30, 2022 | -56.47M |
| March 31, 2022 | -57.78M |
| Date | Value |
|---|---|
| December 31, 2021 | -56.28M |
| September 30, 2021 | -60.25M |
| June 30, 2021 | -59.83M |
| March 31, 2021 | -57.64M |
| December 31, 2020 | -64.60M |
| September 30, 2020 | -57.81M |
| June 30, 2020 | -66.87M |
| March 31, 2020 | -54.07M |
| December 31, 2019 | -54.70M |
| September 30, 2019 | -48.50M |
| June 30, 2019 | -44.50M |
| March 31, 2019 | -32.61M |
| December 31, 2018 | -38.79M |
| September 30, 2018 | -49.40M |
| June 30, 2018 | -32.74M |
| March 31, 2018 | -26.04M |
| December 31, 2017 | -6.45M |
| September 30, 2017 | -0.288M |
Net Income Definition
Represents net income for the period and date(s) requested in local currency by default.
Net Income (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Net Income (Quarterly) Benchmarks
| United Therapeutics Corp. | 333.00M |
| Arbutus Biopharma Corp. | -5.143M |
| Kura Oncology, Inc. | -68.33M |
| ACADIA Pharmaceuticals, Inc. | 31.50M |
| Alnylam Pharmaceuticals, Inc. | 164.49M |
Net Income (Quarterly) Related Metrics
| Revenue (Quarterly) | 9.238M |
| Total Expenses (Quarterly) | -7.662M |
| EPS Diluted (Quarterly) | -6.124 |
| Enterprise Value | 48.91M |
| Gross Profit Margin (Quarterly) | 97.27% |
| Earnings Yield | -550.6% |
| Normalized Earnings Yield | -615.94 |